Colchicine for Gout: Uses, Dosing, and What to Watch For

A gout flare is an alarm going off over something that has been there for years. Urate crystals can sit quietly in a joint for a long time; the agony starts when your immune system suddenly notices them and treats them like an invasion. White blood cells swarm the joint, release inflammatory chemicals, and by the time you are fully awake even the bedsheet is too heavy to bear on your toe.

Colchicine works on the responders, not the crystals. It tells those white cells to stand down, which eases the swelling, heat, and pain of the attack⁴. The crystals are still there when it is over. That matters, because it means colchicine treats the flare you are in, not the gout itself. The medicine that shrinks the crystal supply is a urate-lowering drug like allopurinol, and the two are teammates, not rivals.

For treating a flare, colchicine sits in a first-line trio alongside NSAIDs and steroids. The American College of Rheumatology strongly recommends any of the three, with no single winner¹, and UK guidance from NICE offers the same menu⁷. Which one is right for you comes down to your kidneys, your stomach, your other medicines, and what has worked before.

For decades the standard advice was to keep taking colchicine every hour or two until the pain stopped or your gut rebelled, and it was usually the gut that gave out first. Then a randomized trial called AGREE put that ritual to the test. Low-dose colchicine, 1.8 mg in total over one hour, relieved early flares as well as the old 4.8 mg regimen, with a safety profile the investigators described as indistinguishable from placebo³.

The numbers deserve to be spelled out. On the high-dose schedule, 76.9% of patients got diarrhea. On the low-dose schedule, 23.0% did, and none of those cases were severe³. Same relief, a fraction of the misery. The ACR now strongly recommends low-dose over high-dose colchicine for exactly this reason².

The other half of the low-dose story is safety. Colchicine has a narrow window between a dose that helps and a dose that harms, and the NHS warning is unusually blunt: taking more than your prescribed dose can be very dangerous, and it could be fatal⁵. If a flare is not settling, the answer is a call to your prescriber, not another tablet.

Nothing here is a dosing instruction. Your prescription depends on your kidneys, your liver, and the other medicines you take, so follow it exactly. But it helps to know the shape of the standard regimens, because they differ by country.

In the US, the low-dose pattern studied in the AGREE trial is the common one for a flare: 1.8 mg in total, taken over a single hour at the first sign of the attack, and then stop³. In the UK, the NHS describes a different frame: one 500 microgram tablet taken two to four times a day until symptoms improve, never more than 12 tablets in a course, with a gap of at least three days before starting another⁵. Two systems, one principle: small doses, a hard ceiling, then stop.

Timing matters more than almost anything else here. The trial evidence was built on treating flares early³; colchicine interrupts an immune cascade, and the further that cascade has already run, the less there is left to interrupt. That is a practical argument for having your prescription filled before you need it. Our flare cabinet guide covers what else is worth keeping within reach for the 3 a.m. flare.

Here is the paradox nobody warns you about. Starting a urate-lowering drug can temporarily stir flares up rather than calm them down, as long-settled crystals begin to dissolve and shift. It is the treatment working, and it feels like the treatment failing. People quit allopurinol in those first months believing it made them worse, when what they needed was a guard for the transition.

Guidelines answer with exactly that. The ACR strongly recommends anti-inflammatory prophylaxis for three to six months when starting urate-lowering therapy, rather than less than three, with ongoing review if flares continue². NICE names colchicine first for the job, with a low-dose NSAID or low-dose oral steroid as alternatives when colchicine is unsuitable⁷. The NHS lists preventing gout while starting long-term medicines like allopurinol as one of colchicine's two core uses⁴.

For prevention the dose is small and daily rather than clustered around an attack; the NHS frame is one 500 microgram tablet twice a day⁵. If you are starting allopurinol and nobody has mentioned a preventive medicine to run alongside it, that is a fair question to raise at your next appointment.

Diarrhea is colchicine's signature side effect, and there is no point being delicate about it. At the old high doses, more than three quarters of trial patients got it. At today's low doses, about one in four did, and none of those cases were severe³. Nausea, cramping, and vomiting travel in the same family, and all of them become more likely as doses climb.

Stomach trouble on colchicine is information, not a toughness test. It often means the dose, or how quickly your body is clearing the drug, needs a second look, so tell your prescriber rather than pushing through. Rarer, more serious problems, including effects on muscles and blood cells, have been reported mainly with long-term use, higher doses, or reduced kidney or liver function. Those risks are why this remains a prescription medicine and why the dosing is set so carefully.

While the medicine takes hold, keeping the joint cool can take the edge off. The NHS suggests an ice pack, or a bag of frozen peas, wrapped in a towel and held on for up to 20 minutes⁸. Our cold therapy guide covers how to ice a flaring joint safely and which packs actually fit a foot.

Because the gap between a working dose and a harmful one is narrow, anything that slows colchicine's exit from your body deserves respect. The NHS interaction list includes the antibiotics clarithromycin and erythromycin, the antifungals ketoconazole, itraconazole, and voriconazole, ciclosporin, and the heart medicines verapamil and diltiazem⁶. If you are prescribed any of these while taking colchicine, or the other way around, make sure each prescriber knows about the other.

Two more names are worth raising even though the evidence conversation is more nuanced. If you take a statin for cholesterol, mention it; statins and colchicine are a common pairing in people with gout, and your prescriber and pharmacist will want the full picture when setting doses. You may also see advice to avoid grapefruit juice while on colchicine. Ask your pharmacist about that one; it is a sensible question about anything that changes how the body processes medicines.

Severe kidney or liver disease changes the calculation entirely, and colchicine may not be the right tool at all. In that situation prescribers often reach for a short steroid course or, when the kidneys allow it, an NSAID instead. It is one more argument for making these decisions with someone who can see your whole chart.